Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial) [Original Research Articles]

Conclusions
No change in peak Vo2 occurred at 2 weeks in patients with recently decompensated systolic HF treated with anakinra, whereas an improvement was seen in those patients in whom anakinra was continued for 12 weeks. Additional larger studies are needed to validate the effects of prolonged anakinra on peak Vo2 and rehospitalization for HF.

Clinical Trial Registration
URL: http://www.clinicaltrials.gov. Unique identifier: NCT01936909.

Source: Circulation: Heart Failure - November 15, 2017 Category: Cardiology Authors: Van Tassell, B. W., Canada, J., Carbone, S., Trankle, C., Buckley, L., Oddi Erdle, C., Abouzaki, N. A., Dixon, D., Kadariya, D., Christopher, S., Schatz, A., Regan, J., Viscusi, M., Del Buono, M., Melchior, R., Mankad, P., Lu, J., Sculthorpe, R., Biondi-Z Tags: Inflammation, Translational Studies, Heart Failure Original Research Articles Source Type: research